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KEY POINTS 
Question 
What are the factors modulating risk enrichment in help-seeking subjects referred for clinical 
assessment on suspicion of psychosis risk?  
Findings 
This cohort study that included 710 subjects assessed for suspected psychosis indicated 
substantial six-year risk enrichment (15%) and provided a stratification model that is based on 
ethnicity and source of referral. 
Meaning 
Stratification of risk enrichment in subjects undergoing assessment for suspected psychosis 
risk may inform outreach campaigns, subsequent testing and optimise psychosis prediction. 
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ABSTRACT  
Objective 
To measure the proportion of individuals with a first episode of psychosis detected by At Risk 
Mental State (ARMS) services in secondary mental health services. To develop and 
externally validate a practical web-based individualised risk calculator tool for the 
transdiagnostic prediction of psychosis in secondary mental health care. 
Design 
Clinical register-based cohort study. 
Setting 
Subjects were drawn from electronic, real-world, real-time clinical records relating to 2008-
2015 routine secondary mental health care in South London and Maudsley (SLaM) National 
Health Service (NHS) Foundation Trust. 
Participants 
All patients receiving a first index diagnosis of non-organic and non-psychotic mental 
disorder within SLaM NHS Trust in the period 1st January 2008 to 31st December 2015.  
Main outcome measure 
Risk of development of non-organic ICD-10 psychotic disorders. 
Results 
91199 patients receiving a first index diagnosis of non-organic and non-psychotic mental 
disorder within SLaM NHS Trust were included in the derivation (33820) or external 
validation (54716) datasets. The mean follow-up was 1588 days. The overall 6-year risk of 
psychosis in secondary mental health care was 3.02 (95% CI 2.88 to 3.15), which is higher 
than in the local general population. Compared with the ARMS designation, all of the ICD-10 
diagnoses showed a lower risk of psychosis, with the exception of bipolar mood disorders 
(similar risk) and brief psychotic episodes (higher risk). The ARMS designation accounted 
only for a small proportion of transitions to psychosis (52/1001=5.19% in the derivation 
dataset), indicating the need for transdiagnostic prediction of psychosis in secondary mental 
health care. A prognostic risk stratification model based on preselected variables, including 
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index diagnosis, age, gender, age by gender, and ethnicity was developed and externally 
validated, showing good performance and potential clinical usefulness.  
Conclusions 
The online individualised risk calculator can be of clinical usefulness for the transdiagnostic 
prediction of psychosis in secondary mental health care. The risk calculator can help to 
identify those patients at risk of developing psychosis who require an ARMS assessment and 
specialised care. The use of this calculator may eventually facilitate the implementation of an 
individualised provision of preventative focused interventions and improve outcomes of first 
episode psychosis.  
 
Study registration: researchregistry1487 (www.researchregistry.com), July 31st 2016. Data 
analysis began on September 1st 2016. 
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INTRODUCTION 
Existing treatments for psychotic disorders have little impact on the course of illness under 
standard care.1,2 Prevention and early intervention may be the only available clinical 
possibility to alter the course of psychosis.3 Prevention of psychosis has been feasible since 
the introduction of the At Risk Mental State (ARMS) construct, two decades ago.4 The 
ARMS has been validated internationally,5-7 and it can reliably identify young individuals at 
specific enhanced risk for the development of psychotic disorders8 - mostly schizophrenia 
spectrum disorders9 - but not of non-psychotic disorders,10,11 over the following two to three 
years.12 Randomised controlled trials have shown that focused interventions, if offered to 
ARMS individuals, can effectively reduce the risk of future illness.13,14 Owing to these 
unprecedented potentials, the ARMS has gained traction to the point that specialised 
assessment and treatment is recognised as a key component of secondary mental health 
services by National Institute for Health and Care Excellence (NICE) guidelines.15 
 
However, the overall clinical impact of the ARMS on psychosis prevention in secondary 
mental health care, and the value of using the ARMS designation as compared to standard 
mental diagnoses (e.g. those defined by the International Classification of Disease, 10th 
edition, ICD-10), is not completely clear. For example, the majority of ARMS individuals 
would also meet criteria for a secondary diagnosis of comorbid mental disorder, mostly 
depression or anxiety.16 As a result, some authors have claimed that the ARMS construct is 
not strictly necessary17, and that psychosis could be predicted (and treated) within the existing 
diagnostic categories of common mental disorders.18 Whether we can pragmatically predict 
psychosis outside the ARMS designation or not remains unclear, because no studies have ever 
addressed this issue. Such a gap of knowledge may have clinical implications for the 
provision of preventative intervention services and policy makers. In fact, some authors 
suggest that it would be better to detect and treat psychosis as it emerges from common 
mental disorders rather than promoting new ARMS services.18 To further compound the issue, 
the overall burden of psychosis risk in secondary mental health care is mostly undetermined, 
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and it is not clear whether the ARMS designation is sufficient to pragmatically detect all 
individuals who will later develop a first episode of psychosis. Since ARMS services usually 
receive referrals on suspicion of psychosis risk, it is possible that not all individuals in 
secondary mental health care who will later develop a first episode of psychosis would 
eventually be detected by ARMS services.  
 
The current study advances knowledge by investigating, for the first time, the proportion of 
first episode individuals detected by ARMS services in secondary mental health services as 
well as the transdiagnostic risk of developing psychotic disorders across any ICD-10 defined 
mental disorder. The primary aim was to develop and validate a clinically based, practical, 
individualised risk calculator tool to facilitate the transdiagnostic prediction of psychosis in 
secondary mental health care and increase the proportion of individuals at risk for psychosis 
detected by ARMS services, improving outcomes of first episode psychosis. 
 
METHODS 
Data source 
Clinical register-based cohort selected thorough a Clinical Record Interactive Search (CRIS) 
tool19 (see eMethods 1). 
 
Study population 
All individuals accessing SLaM services in the period 1st January 2008 to 31st December 
2015, and who received a first index primary diagnosis of any non-organic and non-psychotic 
mental disorder, were initially considered eligible. We then excluded those who developed 
psychosis in the three months immediately following the first index diagnosis. Approval for 
the study was granted by the Oxfordshire Research Ethics Committee C. Because the data set 
was made up of deidentified data, informed consent was not required19. 
 
Study measures  
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The outcome (risk of developing any psychotic disorder), predictors (index diagnosis, age, 
gender, ethnicity, and age by gender interaction), and time to event were automatically 
extracted using CRIS.19 Predictors were preselected on the basis of previous meta-analytical 
clinical knowledge, as recommended20 (see eMethods 2 and eTable 1 for full details). 
 
Statistical analysis  
This clinical register-based cohort study was conducted according to the REporting of studies 
Conducted using Observational Routinely-collected health Data (RECORD) Statement21 (see 
supplementary checklist).  
 
Baseline clinical and sociodemographic characteristics of the sample (including missing data) 
were described by means and SDs for continuous variables, and absolute and relative 
frequencies for categorical variables. The overall cumulative risk of psychosis onset in SLaM 
patients was described with the Kaplan–Meier failure function (1  survival)22 and 
Greenwood 95% CIs,23 and was qualitatively compared with the risk of psychosis in the local 
general population (mean predicted cases across SLaM boroughs, estimated with PsyMaptic 
(http://www.psymaptic.org/)).24  
 
Model development and validation followed the guidelines of Royston et al.,25 Steyerberg et 
al.26 and the Transparent Reporting of a multivariable prediction model for Individual 
Prognosis Or Diagnosis (TRIPOD).27  
 
Model development 
We used Cox proportional hazards multivariable complete-case analyses to evaluate the 
effects of the preselected predictors (index diagnosis, age, gender, ethnicity, and age by 
gender interaction) on the development of non-organic ICD-10 psychotic disorders and time 
to development of psychosis, after checking the proportional hazards assumption.28 Model 
development was not based on stepwise methods, which are not recommended,25 but on a-
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priori selection of predictors based on previous knowledge, as detailed in the eMethods 2. 
Continuous variables were not dichotomised.25 Because of significant sociodemographic 
differences between the SLaM boroughs (from29: see Table 1 and Figures 2 and 3), we used 
nonrandom split-sample development and external validation,27 with the Lambeth and 
Southwark cases in the derivation sample and all other cases in the validation sample. The 
model with all preselected predictors was first fitted to the derivation data to estimate the 
optimal regression coefficients. Performance diagnostics of individual predictor variables in 
the derivation dataset were explored with Harrell’s C-index,25 which is similar to the area 
under the receiver operating characteristic curve. We then generated individual prognostic 
scores, allowing a prognostic index (PI) for risk of psychosis onset to be developed in the 
derivation dataset.30 As a supplementary analysis we fitted the model after excluding the 
ATPD cases. 
 
External model validation 
The regression coefficients as estimated in the derivation dataset were then applied to each 
case in the external validation dataset, to generate the PI in the validation dataset. Overall 
model performance (the distance between the predicted outcome and actual outcome26) was 
assessed with the Brier score (the average mean squared difference between predicted 
probabilities and actual outcomes, which also captures calibration and discrimination 
aspects26). A lower score indicates higher precision and less bias, but interpretation depends 
on the incidence of the outcome.26 Overall performance was further investigated with 
Royston’s modification of Nagelkerke’s R2 (indexing the proportion of variation explained by 
the model).31 Calibration (the agreement between observed outcomes and predictions26) was 
assessed with the regression slope of PI26 (which also captures discrimination and model 
fit),25 with the regression intercept (calibration-in-the-large,26 estimated as previously 
detailed32) and with the calibration plot (resampling model calibration with hare function33). 
Discrimination (accurate predictions discriminate between those with and those without the 
outcome26) was addressed with Harrell’s C-index25 and with the discrimination slope 
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(difference in mean of predictions between outcomes26). Recent studies indicate that unbiased 
and precise estimation of performance measures can be achieved with a minimum of 100 
events in the external validation dataset.34  
 
Potential clinical usefulness for psychosis prevention 
We additionally explored the potential clinical utility of the risk calculator as recently 
recommended by Vickers and Steyerberg.35 Performance measures do not tell us whether the 
risk calculator would do more good than harm if used in clinical practice.35 Net benefit (for 
details see35 and36) analyses tackle such limitations by including an exchange rate, a clinical 
judgment of the relative value of benefits (such as preventing psychosis in secondary mental 
health care) and harms (such as unnecessary treatment) associated with the predictive model 
(see details on the exchange rate on eMethods 3). Since definition of the exchange rates is 
subjective, we additionally plotted net benefit for a range of reasonable exchange rates in a 
decision curve analysis, as recommended.35 
 
All analyses were conducted in STATA 13 and R 3.3.0. 
 
RESULTS  
Sociodemographic and clinical characteristics of the sample 
Of 92227 patients receiving a first index diagnosis of non-organic and non-psychotic mental 
disorder within SLaM in the period 2008-2015, 91199 fulfilled the study inclusion criteria 
and were included in the derivation or validation datasets, as indicated in Figure 1. 
 
Table 1 shows the baseline characteristics of the study population, as well as the derivation 
and validation datasets. As expected, there were significant sociodemographic differences 
across the derivation and validation datasets (Table 1), particularly with respect to ethnicity 
and index diagnosis. The mean follow-up was 1588 days (95% CI 1582-1595) with no 
differences between the derivation and validation datasets (derivation: mean 1589, 95% CI 
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1579-1599; validation: mean 1588, 95% CI 1580-1596). The overall risk of developing a 
psychotic disorder is presented in the eResults 1 and eFigure 1 and the baseline hazard 
function in the eFigure 2. 
 
Model development 
In the derivation dataset there were 1001 transitions to psychosis (52 of which were observed 
in the ARMS, 5.19%, eTable 2). The multivariable model significantly predicted psychosis 
onset (likelihood ratio chi-square test=1767.59, p<0.001). Age and male gender were 
significantly associated with an increased risk of psychosis (Table 2). Across males, risk of 
psychosis decreased with increasing age (Table 2). Relative to White ethnicity, Black, Asian, 
mixed, and other ethnicities were associated with an increased risk of developing psychosis 
(Table 2). Compared with the reference ARMS designation, all of the other ICD-10 mental 
disorders were associated with a lower risk of developing psychosis, with two exceptions 
(Table 2). Bipolar mood disorders and acute and transient psychotic disorders showed a 
comparable and higher risk of psychosis than the ARMS, respectively (Table 2). Post-hoc 
analyses showed that relative to the ARMS, bipolar mood disorders and acute and transient 
psychotic disorders had a higher risk of developing affective psychoses (HR= 4.628, 95%CI 
1.655 - 12.941), and schizophrenia spectrum psychoses (HR=5.457, 95%CI 2.742 - 10.893), 
respectively. Supplementary analyses using the APS subgroup of the ARMS as a reference 
group confirmed the model, showing that the BLIPS subgroup was at higher risk of 
developing psychosis than the APS subgroup. Model diagnostics using the C-index are 
detailed in Table 2. The model showed very good overall apparent performance (good 
discrimination, C-index 0.800) and explained approximately 74% of the observed variation 
(Table 3). The model remained significant after removing the ATPD cases (eTable 3). 
 
Model validation 
In the external validation dataset there were 1010 transitions to psychosis (12 of which were 
observed in the ARMS, 1.19%, eTable 2), a value that greatly exceeds the minimum of 100 
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events required for robust external validation.34 The model retained an overall good 
performance and was able to explain around 72% of the observed heterogeneity (Table 3). 
Model discrimination was fair to good, with a C-index of 0.791 (Table 3). The mean risk of 
psychosis in the validation dataset was lower than in the derivation dataset, but there were no 
major miscalibration issues (Table 3 and eFigure 3).    
 
Potential clinical usefulness of the risk calculator 
At the reference threshold for recommending focused interventions to prevent psychosis, the 
use of the model was associated with significant net benefits in both the derivation and 
validation datasets (Table 3). The decision curve estimated in the validation dataset (Figure 2) 
shows that compared to conducting no tests, testing on the basis of the risk calculator is 
associated with net benefits for a 1-50% range of threshold probability (risk of developing 
psychosis by five years, see eResults 2 for an example).  
 
An online version of the risk calculator was built to facilitate numeric calculation of the 
predicted probability of conversion to psychosis in secondary mental health care 
(http://www.psychosis-risk.net).   
 
DISCUSSION  
91199 patients receiving a first index diagnosis of non-organic and non-psychotic mental 
disorder within SLaM were included in the study, either in the derivation (33820) or 
validation (54716) datasets, with a mean follow-up of 1588 days. The overall 6-year risk of 
psychosis in secondary mental health care was 3.02 (95%CI 2.88-3.15) and which is higher 
than the 6-year risk of psychosis in the local general population (0.62). Compared with the 
ARMS designation, all of the other ICD-10 diagnoses were associated with a lower risk of 
psychosis, with two exceptions. Bipolar mood disorders and acute and transient psychotic 
disorders showed a similar and higher risk of psychosis than the ARMS, respectively. The 
ARMS designation accounted only for a small proportion of transitions to psychosis, 
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indicating the need for transdiagnostic prediction of psychosis in secondary mental health 
care. The prognostic risk stratification model based on preselected clinically based variables 
(index diagnosis, age, gender, age by gender, and ethnicity) showed good prognostic accuracy 
in the derivation dataset. The risk calculator was externally validated, confirming good 
performance and potential clinical usefulness for the transdiagnostic prediction of psychosis 
in secondary mental health care.  
This study has three significant clinical implications. First, we confirmed substantial 
psychosis risk enrichment in individuals accessing secondary mental health care. The 6-year 
risk of psychosis was fivefold higher than in the local general population (3.02/0.62=4.87) 
and in individuals accessing primary care,37 highlighting a clear window of opportunity for 
the transdiagnostic prevention of psychosis within secondary mental health care.38  
 
Second, we have shown that the ARMS designation, in particular its APS subgroup (footnotes 
to Table 2) is necessary to predict psychosis in individuals who have never experienced 
psychotic (e.g. BLIPS39) symptoms. The ICD-10 categories of substance use disorders, non-
bipolar mood disorders, anxiety disorders, personality disorders, developmental disorders, 
childhood/adolescence onset disorders, physiological syndromes, and mental retardation 
showed a lower level of psychosis risk. Accordingly, the use of current ICD-10 categories of 
comorbid mental disorders, such as anxiety or depression, is unlikely to be of any clinical 
usefulness to predict psychosis. ICD-10 acute and transient psychotic disorders and the 
BLIPS subgroup of the ARMS were both associated with a very high risk of developing 
psychosis, but only in individuals with remitting symptoms at the time of the index 
diagnosis.40,41 Similarly, bipolar mood disorders specifically predicted the onset of affective-
like psychoses.  
 
Third, we have clearly demonstrated that the ARMS designation, although necessary, is not 
sufficient to intercept the overall burden of psychosis risk in secondary mental health care 
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(see eDiscussion 1). In fact, although OASIS was established in Lambeth and Southwark 
several years before the start of the current cohort,42 only 314 individuals (out of 33820, 
0.93%) were under OASIS care, accounting for only 5.19% of the total cases of emerging 
psychosis across the two boroughs. More importantly, none of the patients outside of OASIS 
care had ever been assessed for an ARMS. This seems like a missed clinical opportunity, 
because screening for an ARMS is specifically indicated for individuals “already distressed 
by mental problems”43 and accessing secondary mental health care,44 to prevent psychosis 
with focused interventions,13 and improve outcomes in those who go on to develop psychosis 
(by reducing the duration of untreated psychosis, admission to hospital and compulsory 
treatments45 or unnecessary treatment46).  
 
Building on the aforementioned points, our findings highlight a significant unmet need for 
transdiagnostic prevention of psychosis in secondary mental health care, which is not 
currently addressed by existing ICD-10 categories (that are not specific enough for psychosis 
prediction) or the ARMS designation (which does not include the majority of individuals at 
risk for psychosis). To overcome these limitations, this study developed a practical, 
individualised risk calculator tool for the transdiagnostic prediction of psychosis in secondary 
mental health care. A well-performing risk calculator was developed from easily collectable 
clinical and demographic predictor variables (age, gender, age by gender, ethnicity, index 
ICD-10/ARMS diagnosis). The overall validated model was robust and achieved good 
performance, which is in the range of values for established calculators currently in use for 
cancer and cardiovascular, neurological and endocrine diseases (see Table 3 in5). The risk 
calculator was implemented online and designed to generate a number representing the 
probability of transition to psychosis, given a particular profile of input variables. A key 
advantage of the risk calculator is that it inherently accommodates heterogeneity in profiles of 
risk factors among high-risk individuals.47,48 At the same time, the risk calculator assumes 
that individuals have accessed secondary mental health care and that the predictor variables 
are coded as indicated in our methods (e.g. ICD-10 categories for the index diagnosis). 
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Therefore, the risk prediction tool would not be usable in primary care or the general 
population, or if other diagnostic criteria have been used (e.g. DSM). 
 
This tool is therefore most useful to clinicians using the calculator for patients who have 
accessed secondary mental health services. The online calculator could also be easily 
integrated into electronic case registers such as CRIS, to facilitate the automatic and 
individualised prediction of psychosis. Critically, risk determinations should be 
communicated to patients by clinicians who can help patients understand the meaning of the 
risk estimates and provide commensurate treatment recommendations. The decision curve 
analysis presented in our study can further help clinicians to tailor individualised focused 
interventions, such as selecting patients to be referred to ARMS services. Focused 
interventions may include a detailed clinical assessment for psychosis risk (i.e. the ARMS 
assessment) combined with sequential testing,49,50 close-in clinical monitoring for the 
emergence of psychosis, and psychological treatments currently recommended to prevent 
psychosis.  
 
Future studies are needed to refine the focused interventions targeting the high-risk 
individuals detected by our risk calculator. It is also possible that not all high-risk individuals, 
even if properly referred and assessed, would eventually meet ARMS criteria. For example, 
research in high-risk individuals with an index diagnosis of bipolar disorders may help to 
refine the ARMS construct and its ability to predict the onset of affective psychoses.51 
Similarly, the effectiveness of preventative psychological treatments in individuals deemed at 
risk by our calculator, but not meeting ARMS criteria, should be further investigated. 
Limitations of the study have been addressed in the eDiscussion 2 section. 
 
CONCLUSIONS 
Individuals accessing secondary mental health services are at enhanced risk of developing 
psychosis compared to the local general population. The use of this novel individualised risk 
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calculator can be of clinical usefulness for the transdiagnostic prediction and prevention of 
psychosis in secondary mental health care.  
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Figure 1. Flow chart of study population 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Patients receiving a first index diagnosis of non-
organic and non-psychotic mental disorder within 
SLaM in the period 2008-2015 (n=92 227). 
Individuals assessed on suspicion of psychosis risk 
but not meeting ARMS criteria not included. 
Final study population                              
(n=91 199) 
Excluded due to development of 
psychosis in the first three months 
following index diagnosis (n=1028) 
Missing borough data                              
(n= 2663, 2.92%) 
Derivation dataset (boroughs of 
Lambeth and Southwark)                              
(n= 33820, 37.08%) 
Validation dataset (any other 
borough)                                          
(n= 54716, 60%) 
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Table 1. Sociodemographic characteristics of study population, including the derivation and validation dataset 
    
Study population 
(n= 91199)(a) 
Derivation dataset 
(n=33820) 
Validation dataset 
(n=54716) 
Validation vs 
Derivation  
    Mean SD Mean SD Mean SD t P 
Age (years)(a) 32.97 18.63 34.4 18.92 31.98 18.54 18.73 <0.001 
    Count % Count % Count % X2 P 
Gender 
      
13.37 <0.001 
 
Male 46404 50.88 17303 48.81 27302 49.9 
  
 
Female 44761 49.08 16507 51.16 27398 50.07 
  
 
Missing 34 0.04 10 0.03 16 0.03 
  Ethnicity 
      
50.21 <0.001 
 
Black 14327 15.71 6879 20.34 7023 12.84 
  
 
White 55679 61.05 18627 55.08 35392 64.68 
  
 
Asian 3830 4.2 1129 3.34 2608 4.77 
  
 
Mixed 3319 3.64 1306 3.86 1957 3.58 
  
 
Other 5700 6.25 3466 10.25 2084 3.81 
  
 
Missing 8344 9.15 2413 7.13 5652 10.33 
  Index diagnosis 
      
48.2 <0.001 
 
ARMS  368 0.4 314 0.93 50 0.09 
  
 
Acute and transient psychotic disorders 1370 1.5 553 1.64 725 1.33 
  
 
Substance use disorders 14689 16.11 7149 21.14 6507 11.89 
  
 
Bipolar mood disorders 2558 2.8 950 2.81 1526 2.79 
  
 
Non bipolar mood disorders 15496 16.99 6302 18.63 8841 16.16 
  
 
Anxiety disorders 24770 27.16 8235 24.35 15960 29.17 
  
 
Personality disorders 3562 3.91 1286 3.8 2116 3.87 
  
 
Developmental disorders 5192 5.69 1412 4.18 3706 6.77 
  
 
Childhood/adolescence onset disorders 13984 15.33 4200 12.42 9629 17.6 
  
 
Physiological syndromes 7053 7.73 2555 7.55 4424 8.09 
  
 
Mental retardation 2157 2.37 864 2.55 1232 2.25 
  
(a) SLaM boroughs used to define the derivation (Lambeth and Southwark) and validation (any other) datasets: Lambeth and Southwark 33820 (37.08%), any 
others 54716 (60.00%), missing 2663 (2.92%) 
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Table 2. Statistics for individual predictor variables in the multivariable Cox proportional hazards 
regression analysis of risk for psychosis in the derivation dataset  
  
Multivariable model   Harrell's C (a) 
Predictor  
Hazard 
Ratio 
95% CI P 
 
Decrement 
if removed 
Increase if 
added (b) 
Age (years) 1.011 1.001 1.017 <0.001   <0.001 n/a  
Gender  
 
    
<0.001 0.004 
 
Male 1.764 1.298 2.399 <0.001 
   
 
Female 1 
      
Age by gender (male) 0.988 0.981 0.995 0.001 
 
0.001 <0.001 
Ethnicity  
 
    
0.032 0.105 
 
White 1 
      
 
Black 2.823 2.438 3.268 <0.001 
   
 
Asian 1.671 1.215 2.298 0.002 
   
 
Mixed 1.839 1.276 2.626 0.001 
   
 
Other 1.504 1.210 1.869 <0.001 
   
Index diagnosis 
 
    
0.127 0.196 
 
ARMS (c) 1 
      
 
Acute and transient 
psychotic disorders 
2.682 1.981 3.631 <0.001 
   
 
Substance use disorders 0.146 0.105 0.202 <0.001 
   
 
Bipolar mood disorders 0.839 0.598 1.178 0.310 
   
 
Non bipolar mood 
disorders 
0.152 0.109 0.210 <0.001 
   
 
Anxiety disorders 0.107 0.077 0.148 <0.001 
   
 
Personality disorders 0.213 0.141 0.321 <0.001 
   
 
Developmental disorders 0.031 0.015 0.064 <0.001 
   
 
Childhood/adolescence 
onset disorders 
0.039 0.025 0.061 <0.001 
   
 
Physiological syndromes 0.085 0.052 0.137 <0.001 
   
 
Mental retardation 0.086 0.049 0.151 <0.001 
   
(a) The C-index of the overall model was 0.800 (95% CI 0.785-0.816);  
(b) a base model was used which included only the predictor age; the C-index for the base model was 0.567 
(95%CI 0.552-0.581);  
(c) when the APS subgroup of the ARMS was used as reference group the overall results were unchanged 
(likelihood ratio chi-square test=1772.83, p<0.001):  
°Age: 1.012 (95%CI 1.007 - 1.017);  
°Gender: Female 1, Male 1.775 (95%CI 1.305 - 2.415); 
°Age by Gender: Male .988 (95%CI .980 - .995);  
°Ethnicity: White 1, Black 2.819 (95%CI 2.436 - 3.264), Asian 1.683  (95%CI 1.223 - 2.314), Mixed 1.827 
(95%CI 1.274 - 2.621), Other 1.504 (95%CI 1.210 - 1.869); 
°Index diagnosis: APS 1, BLIPS 1.944 (95%CI 1.053 - 3.590), GRD not estimated (5 cases and 0 events), 
Acute and transient psychotic disorders 3.054 (95% 2.162 - 4.315), Substance use disorders 0.166 (95%CI 
0.115 - 0.239), Bipolar mood disorders 0.956 (95%CI 0.655 - 1.396), Non bipolar mood disorders 0.173 
(95%CI 0.119 - 0.249), Anxiety disorders 0.122 (95%CI 0.085 - 0.176), Personality disorders 0.242 
(95%CI 0.156 - 0.377), Developmental disorders 0.035 (95%CI 0.017 - 0.074), Childhood/adolescence 
onset disorders 0.044 (95%CI 0.027 - 0.071), Physiological syndromes 0.097 (95%CI 0.059 - 0.161), 
Mental retardation 0.098 (95%CI 0.055 -   0.177).   
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Table 3. Performance of the risk calculator for transdiagnostic prediction of psychosis in 
secondary mental health care and clinical usefulness 
Performance measure Derivation   Validation 
Overall  
       
 
Brier (a) 0.025 
   
0.019 
  
 
R2 (mean, 95% CI) 0.747 0.705 0.786 
 
0.72 0.673 0.762 
Discrimination 
       
 
Harrell's C (mean, 95%CI) 0.800 0.785 0.816 
 
0.791 0.778 0.807 
 
Discrimination slope (mean, 95% CI) 1.465 1.412 1.518 
 
1.408 1.353 1.462 
Calibration 
       
 
Calibration-in-the-large 0 
   
0.005 
  
 
Calibration slope (mean, 95%CI) 1 
   
0.956 0.909 1.003 
Clinical usefulness  
       
 
Net benefit at 7.69%(b) 0.053 
   
0.061 
  a) at 10-year, b) compared to treat all at 5-year  
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Figure 2. Decision curve analysis estimated in the validation dataset, showing the potential clinical usefulness 
of the risk calculator at different threshold probabilities (risk of developing psychosis by 5 years) for focused 
interventions to prevent psychosis, as compared to treating all patients or to treating no patients at all.  
 
